These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35751974)

  • 21. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.
    Wu Y; Zhang H; Meng L; Li F; Yu C
    Front Immunol; 2022; 13():906457. PubMed ID: 35663946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice.
    Lu M; Liu K; Peng Y; Ding Z; Li Y; Tendu A; Hu X; Gao G; Guo W; Liu H; Rao J; Zhao J; Chen M; Yuan Z; Wong G; Shan C; Yao Y; Lan J
    Virol Sin; 2022 Aug; 37(4):581-590. PubMed ID: 35659605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    Zhang T; Wang Z; Yang J; Xu X
    J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
    Homma T; Nagata N; Hashimoto M; Iwata-Yoshikawa N; Seki NM; Shiwa-Sudo N; Ainai A; Dohi K; Nikaido E; Mukai A; Ukai Y; Nakagawa T; Shimo Y; Maeda H; Shirai S; Aoki M; Sonoyama T; Sato M; Fumoto M; Nagira M; Nakata F; Hashiguchi T; Suzuki T; Omoto S; Hasegawa H
    Sci Rep; 2022 Dec; 12(1):20861. PubMed ID: 36460696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
    Eldi P; Cooper TH; Prow NA; Liu L; Heinemann GK; Zhang VJ; Trinidad AD; Guzman-Genuino RM; Wulff P; Hobbs LM; Diener KR; Hayball JD
    Immunol Cell Biol; 2022 Apr; 100(4):250-266. PubMed ID: 35188985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
    Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
    Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
    Kim GN; Choi JA; Wu K; Saeedian N; Yang E; Park H; Woo SJ; Lim G; Kim SG; Eo SK; Jeong HW; Kim T; Chang JH; Seo SH; Kim NH; Choi E; Choo S; Lee S; Winterborn A; Li Y; Parham K; Donovan JM; Fenton B; Dikeakos JD; Dekaban GA; Haeryfar SMM; Troyer RM; Arts EJ; Barr SD; Song M; Kang CY
    PLoS Pathog; 2021 Dec; 17(12):e1010092. PubMed ID: 34914812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.
    Rappaport AR; Hong SJ; Scallan CD; Gitlin L; Akoopie A; Boucher GR; Egorova M; Espinosa JA; Fidanza M; Kachura MA; Shen A; Sivko G; Van Abbema A; Veres RL; Jooss K
    Nat Commun; 2022 Jun; 13(1):3289. PubMed ID: 35672369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.